{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:05:10Z","timestamp":1772276710520,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12149-025-02036-5","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T10:40:24Z","timestamp":1741344024000},"page":"588-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ga-68 Pentixafor PET\/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study"],"prefix":"10.1007","volume":"39","author":[{"given":"Dinesh Kumar","family":"Gauthaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indirani","family":"Muthukrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Ashish","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6612-8703","authenticated-orcid":false,"given":"Shelley","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2036_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(09)60221-X.","journal-title":"Lancet"},{"key":"2036_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cncr.20288","volume":"101","author":"A Jemal","year":"2004","unstructured":"Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975\u20132001, with a special feature regarding survival. Cancer. 2004;101:3\u201327. https:\/\/doi.org\/10.1002\/cncr.20288.","journal-title":"Cancer"},{"key":"2036_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1148\/rg.301095066","volume":"30","author":"CJ Hanrahan","year":"2010","unstructured":"Hanrahan CJ, Christensen CR, Crim JR. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET\/CT. Radiographics. 2010;30:127\u201342. https:\/\/doi.org\/10.1148\/rg.301095066.","journal-title":"Radiographics"},{"key":"2036_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00277-009-0829-0","volume":"88","author":"S Lutje","year":"2009","unstructured":"Lutje S, de Rooy JWJ, Croockewit S, Koedam E, Oyen WJG, Raymakers RA. Role of radiography, MRI and FDG-PET\/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009;88:1161\u20138. https:\/\/doi.org\/10.1007\/s00277-009-0829-0.","journal-title":"Ann Hematol"},{"key":"2036_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2967\/jnumed.111.098830","volume":"53","author":"RC Walker","year":"2012","unstructured":"Walker RC, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53:1091\u2013101. https:\/\/doi.org\/10.2967\/jnumed.111.098830.","journal-title":"J Nucl Med"},{"key":"2036_CR6","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","journal-title":"Blood"},{"key":"2036_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/RLU.0b013e3181b06bc5","volume":"34","author":"A Dimitrakopoulou-Strauss","year":"2009","unstructured":"Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34:576\u201384. https:\/\/doi.org\/10.1097\/RLU.0b013e3181b06bc5.","journal-title":"Clin Nucl Med"},{"key":"2036_CR8","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/s1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET\/CTin the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"2036_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of F-18-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50\u20135.","journal-title":"Haematologica"},{"key":"2036_CR10","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","volume":"81","author":"P Spinnato","year":"2012","unstructured":"Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U, et al. Contrast enhanced MRI and (1)(8)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81:4013\u20138. https:\/\/doi.org\/10.1016\/j.ejrad.2012.06.028.","journal-title":"Eur J Radiol"},{"key":"2036_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","volume":"33","author":"C Nanni","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of F-18-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525\u201331. https:\/\/doi.org\/10.1007\/s00259-005-0004-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2036_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134. https:\/\/doi.org\/10.1182\/blood-2017-03-774422.","journal-title":"Blood"},{"key":"2036_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414\u201321. https:\/\/doi.org\/10.1007\/s00259-015-3200-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2036_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with (68) Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47(3):537\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2036_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, Herrmann K, et al. [(68) Ga] Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma\u2014comparison to [(18)F] FDG and laboratory values. Theranostics. 2017;7(1):205\u201312. https:\/\/doi.org\/10.7150\/thno.16576.","journal-title":"Theranostics"},{"issue":"8","key":"2036_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","volume":"32","author":"M Kircher","year":"2018","unstructured":"Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, et al. CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med. 2018;32(8):503\u201311.","journal-title":"Ann Nucl Med"},{"issue":"6","key":"2036_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, Hanscheid H, Luckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7(6):1589\u201397.","journal-title":"Theranostics"},{"key":"2036_CR18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211272","author":"AS Shekhawat","year":"2022","unstructured":"Shekhawat AS, Singh B, Malhotra P, Watts A, Basher R, Kaur H, et al. Imaging CXCR4 receptors expression for staging multiple myeloma by using Ga-68-Pentixafor PET\/CT: comparison with F-18-FDG PET\/CT. Br J Radiol. 2022. https:\/\/doi.org\/10.1259\/bjr.20211272.","journal-title":"Br J Radiol"},{"issue":"10","key":"2036_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","volume":"35","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Isik EG, Tiryaki TO, Has-Simsek D, Sanli Y, Buyukkaya F, \u00d6zkan ZG, Kalayoglu-Besisik S, Unal SN. Prognostic significance of Ga-68-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to F-18-FDG PET\/CT and laboratory results. Ann Nucl Med. 2021;35(10):1147\u201356. https:\/\/doi.org\/10.1007\/s12149-021-01652-1.","journal-title":"Ann Nucl Med"},{"key":"2036_CR20","first-page":"1","volume":"30","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, Zhang J, Liu H, Zeng Z, Miao W. [68Ga] Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F] FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2024;30:1\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2036_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","volume":"42","author":"BG Durie","year":"2006","unstructured":"Durie BG. The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.037.","journal-title":"Eur J Cancer"},{"issue":"15","key":"2036_CR22","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2036_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, et al. Ga-68-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for Prostate Cancer Imaging: Version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2036_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"8","key":"2036_CR25","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D van Lammeren-Venema","year":"2012","unstructured":"van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. F-18-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118(8):1971\u201381.","journal-title":"Cancer"},{"key":"2036_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30309-2","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BG, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019. https:\/\/doi.org\/10.1016\/s1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"key":"2036_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mri.2020.10.005","volume":"75","author":"A Latifoltojar","year":"2021","unstructured":"Latifoltojar A, Boyd K, Riddell A, Kaiser M, Messiou C. Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: towards macro-phenotype driven patient management. Magn Reson Imaging. 2021;75:60\u20134. https:\/\/doi.org\/10.1016\/j.mri.2020.10.005.","journal-title":"Magn Reson Imaging"},{"issue":"7","key":"2036_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2036_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/RLU.0000000000002166","volume":"43","author":"S Kuyumcu","year":"2018","unstructured":"Kuyumcu S, Yilmaz E, Buyukkaya F, Ozkan ZG, Unal SN. Imaging of chemokine receptor CXCR4 in mycosis fungoides using Ga-68-Pentixafor PET\/CT. Clin Nucl Med. 2018;43(8):606.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2036_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2008;23(1):3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291.","journal-title":"Leukemia"},{"issue":"2","key":"2036_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdp329.","journal-title":"Ann Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:13:36Z","timestamp":1747800816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2036"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02036-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5135393\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}